Anti-phospholipid antibodies, neuroleptic treatment and cardiovascular morbidity [5]

British Journal of Psychiatry

Volumn 190, Issue JAN., 2007, Pages 81-

  Leuci, E ^a   Manenti, L ^b   Maggini, C ^a  

^a Psychiatry Department   (Italy)

^b ASL Parma   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; NEUROLEPTIC AGENT; PHOSPHOLIPID ANTIBODY;

ARTERY THROMBOSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HEART INFARCTION; HUMAN; LETTER; LUNG EMBOLISM; MORBIDITY; PSYCHOSIS; RESPIRATORY TRACT DISEASE; RISK FACTOR; RISK REDUCTION; SCHIZOPHRENIA; THROMBOSIS PREVENTION; VEIN THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; ANTIPSYCHOTIC AGENTS; HUMANS; MENTAL DISORDERS; THROMBOSIS;

EID: 33846291879     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.190.1.81     Document Type: Letter

References (5)

1. Chengappa, K. N., Carpenter, A. B., Keshavan, M. S. et al (1991) Elevated IGG and IGM anticardiolipin antibodies in a subgroup of medicated and unmedicated shizophrenic patients. Biological Psychiatry, 30, 731-735.
2. Erkan, D. & Lockshin, M. D. (2006) Antiphospholipid syndrome. Current Opinion in Rheumatology, 18, 242-248.
3. Joukamaa, M., Heliövaara, M., Knekt, P., et al (2006) Schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry, 188, 122-127.
4. Oomen, H. A., Wekking, F. M., de Jong, J., et al (1995) Screening psychiatric admissions for anticardiolipin antibody. Psychiatry Research, 58, 83-88.
5. Schwartz, M. D., Rochas, M., Weller, B. et al (1998) High association of anticardiolipin antibodies with psychosis. Journal of Clinical Psychiatry, 59, 20-23.